Simon Portsmouth

4.1k total citations · 3 hit papers
62 papers, 2.9k citations indexed

About

Simon Portsmouth is a scholar working on Epidemiology, Infectious Diseases and Virology. According to data from OpenAlex, Simon Portsmouth has authored 62 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Epidemiology, 26 papers in Infectious Diseases and 24 papers in Virology. Recurrent topics in Simon Portsmouth's work include HIV Research and Treatment (24 papers), HIV/AIDS drug development and treatment (20 papers) and Antibiotics Pharmacokinetics and Efficacy (14 papers). Simon Portsmouth is often cited by papers focused on HIV Research and Treatment (24 papers), HIV/AIDS drug development and treatment (20 papers) and Antibiotics Pharmacokinetics and Efficacy (14 papers). Simon Portsmouth collaborates with scholars based in United States, United Kingdom and Japan. Simon Portsmouth's co-authors include Roger Echols, Tsutae Den Nagata, Mari Ariyasu, Takeki Uehara, Kenji J. Tsuchiya, Takao Shishido, Frederick G. Hayden, Justin Stebbing, Mark Bower and Brian Gazzard and has published in prestigious journals such as New England Journal of Medicine, Blood and Clinical Infectious Diseases.

In The Last Decade

Simon Portsmouth

62 papers receiving 2.9k citations

Hit Papers

Baloxavir Marboxil for Uncomplicated Influenza in Adults ... 2018 2026 2020 2023 2018 2020 2018 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
    2018 595 citations Frederick G. Hayden, Nobuo Hirotsu et al. profile →
  2. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
    2020 540 citations Matteo Bassetti, Roger Echols et al. The Lancet Infectious Diseases profile →
  3. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
    2018 305 citations Simon Portsmouth, Roger Echols et al. The Lancet Infectious Diseases profile →

Peers

Simon Portsmouth
Bruce Polsky United States
Athanasios Skoutelis Greece
Joan R. Butterton United States
Yu‐Chung Chuang Taiwan
Vana Sypsa Greece
Emanuele Durante‐Mangoni Italy
Valerio Del Bono Italy
Francisc Schlaeffer Israel
Stephen Villano United States
Helmut Albrecht United States
Bruce Polsky United States
Simon Portsmouth
Citations per year, relative to Simon Portsmouth Simon Portsmouth (= 1×) peers Bruce Polsky

Countries citing papers authored by Simon Portsmouth

Since Specialization
Citations

This map shows the geographic impact of Simon Portsmouth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Portsmouth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Portsmouth more than expected).

Fields of papers citing papers by Simon Portsmouth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Portsmouth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Portsmouth. The network helps show where Simon Portsmouth may publish in the future.

Co-authorship network of co-authors of Simon Portsmouth

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Portsmouth. A scholar is included among the top collaborators of Simon Portsmouth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Portsmouth. Simon Portsmouth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Satlin, Michael J., et al.. (2023). Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program. Antimicrobial Agents and Chemotherapy. 67(7). e0019423–e0019423. 24 indexed citations
3.
Portsmouth, Simon, Almasa Bass, Roger Echols, & Glenn Tillotson. (2021). Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials. Open Forum Infectious Diseases. 8(3). ofab045–ofab045. 9 indexed citations
4.
Matsunaga, Yuko, Takuhiro Sonoyama, Luís Casanova, et al.. (2020). 1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections. Open Forum Infectious Diseases. 7(Supplement_1). S661–S662. 8 indexed citations
5.
Bassetti, Matteo, Roger Echols, Yuko Matsunaga, et al.. (2020). 1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study. Open Forum Infectious Diseases. 7(Supplement_1). S652–S653. 2 indexed citations
6.
Ison, Michael G., Simon Portsmouth, Yuki Yoshida, et al.. (2020). Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. The Lancet Infectious Diseases. 20(10). 1204–1214. 166 indexed citations
7.
Watanabe, Akira, Tadashi Ishida, Nobuo Hirotsu, et al.. (2019). Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study. Antiviral Research. 163. 75–81. 22 indexed citations
8.
Nelson, Mark, Rafael Rubio, Adriano Lazzarin, et al.. (2017). Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. Journal of Interferon & Cytokine Research. 37(3). 103–111. 13 indexed citations
9.
Flisiak, Robert, Seiji Kawazoe, Nimer Assy, et al.. (2016). Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. Journal of Interferon & Cytokine Research. 36(11). 635–643. 10 indexed citations
10.
Gulick, Roy M., Gerd Fätkenheuer, William D. Hardy, et al.. (2013). Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 65(1). 78–81. 31 indexed citations
11.
Furtado, Juvêncio José Duailibe, José Valdez Madruga, Max Igor Banks Ferreira Lopes, et al.. (2013). Safety and Immunovirologic Outcomes with Maraviroc Combination Regimens in Patients with a History of Past Treatment Failures and Virologic Resistance in Brazil: An Open-Label, Multicenter Phase 3b Study. AIDS Research and Human Retroviruses. 29(9). 1203–1210. 5 indexed citations
12.
Lee, Guinevere Q., P. Richard Harrigan, Winnie Dong, et al.. (2013). Comparison of Population and 454 “Deep” Sequence Analysis for HIV Type 1 Tropism Versus the Original Trofile Assay in Non-B Subtypes. AIDS Research and Human Retroviruses. 29(6). 979–984. 14 indexed citations
13.
Swenson, Luke C., Theresa Mo, Winnie Dong, et al.. (2011). Deep V3 Sequencing for HIV Type 1 Tropism in Treatment-Naive Patients: A Reanalysis of the MERIT Trial of Maraviroc. Clinical Infectious Diseases. 53(7). 732–742. 79 indexed citations
14.
Barber, Tristan, et al.. (2007). Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice?. AIDS. 21(13). 1823–1824. 4 indexed citations
15.
Stebbing, Justin, Steve Patterson, Simon Portsmouth, et al.. (2004). Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patients. Cell Research. 14(3). 251–256. 8 indexed citations
16.
Stebbing, Justin, Simon Portsmouth, & Mark Bower. (2003). Insights into the molecular biology and sero-epidemiology of Kaposiʼs sarcoma. Current Opinion in Infectious Diseases. 16(1). 25–31. 24 indexed citations
17.
Stebbing, Justin, Simon Portsmouth, Mark Nelson, et al.. (2003). The efficacy of ritonavir in the prevention of AIDS‐related Kaposi's sarcoma. International Journal of Cancer. 108(4). 631–633. 22 indexed citations
18.
Portsmouth, Simon, Justin Stebbing, & Brian Gazzard. (2003). Current Treatment of HIV Infection. Current Topics in Medicinal Chemistry. 3(13). 1458–1466. 13 indexed citations
19.
Stebbing, Justin, Adrian Wildfire, Simon Portsmouth, et al.. (2003). Paclitaxel for anthracycline-resistant AIDS-related Kaposi’s sarcoma: clinical and angiogenic correlations. Annals of Oncology. 14(11). 1660–1666. 39 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bruce Polsky Breakdown of academic impact, for papers by Athanasios Skoutelis Breakdown of academic impact, for papers by Joan R. Butterton Breakdown of academic impact, for papers by Yu‐Chung Chuang Breakdown of academic impact, for papers by Vana Sypsa Breakdown of academic impact, for papers by Emanuele Durante‐Mangoni Breakdown of academic impact, for papers by Valerio Del Bono Breakdown of academic impact, for papers by Francisc Schlaeffer Breakdown of academic impact, for papers by Stephen Villano Breakdown of academic impact, for papers by Helmut Albrecht
Rankless by CCL
2026